Press Releases

Back to previous page

ReGen Biologics Retains Cameron Associates as Investor Relations Advisor

FRANKLIN LAKES, N.J.--(BUSINESS WIRE)--Oct. 28, 2003--ReGen Biologics, Inc. (OTC: RGBI) (BB:RGBI), a leading orthopedic products company that develops and manufactures tissue repair products for unmet markets both in the U.S. and globally, today announced that it has retained Cameron Associates, Inc. as its investor relations advisor. Cameron Associates is a 27-year-old New York-based, full-service investor relations firm that represents a wide variety of publicly-held companies in the U.S.

Cameron will assist ReGen Biologics, Inc., www.regenbio.com, in broadening its financial market presence and establishing new relationships within the investment community and financial media. The firm has a wealth of experience representing rapidly growing, emerging health care and technology companies.

Gerald E. Bisbee, Jr., Ph.D., Chairman, President, and CEO of ReGen Biologics, Inc. commented. "I am very pleased with our appointment of Cameron Associates. We expect our relationship with Cameron to enhance the visibility and value of the Company as we introduce our products and business strategies to a wider audience." Dr. Bisbee continued, "We believe Cameron's experience and knowledge of the investment industry, and particularly its experience with small public companies, will serve ReGen and its shareholders well."

Founded in 1976, Cameron Associates, Inc. is a New York City-based, full-service investor relations firm providing strategic counsel to a select group of public companies. Additional information about Cameron Associates can be obtained on the Web at www.cameronassoc.com.

About ReGen Biologics, Inc.
ReGen Biologics is an orthopedic products company that develops and manufactures tissue repair products for unmet markets, both in the U.S. and globally. ReGen's first product using its patented core technology is the CMI, which uses the body's own healing process to grow new meniscus tissue and restore mobility for patients with meniscus loss. ReGen completed enrollment and surgeries in the CMI U.S. Multicenter Clinical Trial in November 2002, with submission of the PMA to the FDA expected in the second half of 2004. The CMI is currently distributed in Europe, Australia, Chile and certain other countries through Centerpulse (NYSE:CEP - News) and it is expected to be selectively available in Canada during 2003. For more information on ReGen's next generation tissue regeneration products, visit www.regenbio.com, call (201) 651-5140, or email info@regenbio.com.

This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of the managements of ReGen and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission on August 14, 2003. ReGen's filings with the SEC are available to the public at the Company's website at http://www.regenbio.com, from commercial document-retrieval services, and at the Web site maintained by the SEC at http://www.sec.gov.

CONTACT:
ReGen Biologics, Inc.
Brion D. Umidi
410-349-2431
bumidi@regenbio.com

Cameron Associates
Lester Rosenkrantz
212-554-5486
lester@cameronassoc.com